SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.
The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)